Richard Porter
Directeur Technique/Scientifique/R&D chez UNIQURE N.V.
Fortune : 164 419 $ au 31/05/2024
Profil
Richard Porter is the founder of uniQure France SAS, which was founded in 2019.
He held the title of Chief Executive Officer & Director at uniQure France SAS.
Currently, Dr. Porter is the Chief Business & Scientific Officer at uniQure NV, starting in 2021.
Dr. Porter's former positions include General Manager-Product at Shire Plc from 2011 to 2014, Global Head-Scientific Business Strategy at Roche Group from 2014 to 2016, and Chief Operating Officer at Therachon AG from 2016 to 2019.
Dr. Porter obtained a doctorate degree from The University of Southampton.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
UNIQURE N.V.
0,07% | 31/03/2024 | 33 216 ( 0,07% ) | 164 419 $ | 31/05/2024 |
Postes actifs de Richard Porter
| Sociétés | Poste | Début |
|---|---|---|
| UNIQURE N.V. | Directeur Technique/Scientifique/R&D | 05/10/2023 |
Anciens postes connus de Richard Porter
| Sociétés | Poste | Fin |
|---|---|---|
| Therachon AG | Directeur des opérations | 01/07/2019 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Directeur Technique/Scientifique/R&D | 01/08/2016 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/02/2014 |
Corlieve Therapeutics SAS
 Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Fondateur | - |
Formation de Richard Porter
| The University of Southampton | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
| Therachon AG | |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
